A recombinant truncated surface immunogenic protein (tSip) plus adjuvant FIA confers active protection against Group B streptococcus infection in tilapia

Yang He; Kai-Yu Wang; Dan Xiao; De-Fang Chen; Lingyuan Huang; Tianqiang Liu; Jun Wang; Yi Geng; Er-Long Wang; Qian Yang

doi:10.1016/j.vaccine.2014.08.017

A recombinant truncated surface immunogenic protein (tSip) plus adjuvant FIA confers active protection against Group B streptococcus infection in tilapia

Vaccine. 2014 Dec 5;32(51):7025-7032. doi: 10.1016/j.vaccine.2014.08.017. Epub 2014 Oct 16.

Authors

Yang He¹, Kai-Yu Wang², Dan Xiao³, De-Fang Chen⁴, Lingyuan Huang¹, Tianqiang Liu³, Jun Wang¹, Yi Geng⁵, Er-Long Wang¹, Qian Yang¹

Affiliations

¹ Department of Basic Veterinary, Veterinary Medicine College, Sichuan Agricultural University, Ya'an 625014, Sichuan, PR China.
² Department of Basic Veterinary, Veterinary Medicine College, Sichuan Agricultural University, Ya'an 625014, Sichuan, PR China; Key Laboratory of Animal Disease and Human Health of Sichuan Province, Sichuan Agricultural University, Ya'an 625014, Sichuan, PR China. Electronic address: kywang@sicau.edu.cn.
³ Animal Health Research Institute of Tongwei Co., Ltd., Chengdu 610041, Sichuan, PR China.
⁴ Department of Aquaculture, College of Animal Science& Technology, Sichuan Agricultural University, Ya'an, Sichuan 625014, PR China.
⁵ Department of Basic Veterinary, Veterinary Medicine College, Sichuan Agricultural University, Ya'an 625014, Sichuan, PR China; Key Laboratory of Animal Disease and Human Health of Sichuan Province, Sichuan Agricultural University, Ya'an 625014, Sichuan, PR China.

PMID: 25446833
DOI: 10.1016/j.vaccine.2014.08.017

Abstract

Purpose: Tilapia is an important agricultural fish that has been plagued by Group B streptococcus (GBS) infections in recent years, some of them severe. It is well-known that surface immunogenicity protein (Sip) is an effective vaccine against GBS.

Experimental design: Since Sip was not expressed in either E. coli BL21 or E. coli Rosetta, we removed the N-terminal signal peptide and LysM of the virus to produce purified truncated Sip (tSip(1)), which multiplied easily in an E. coli host. The antibody's ability to recognize and combine with GBS was determined by Western-blot and specific staining in vitro. The relative percentage of survival (RPS), antibody titers, bacterial recovery, and pathologic morphology were monitored in vivo to evaluate the immune effects. Freund's incomplete adjuvant (FIA) plus tSip and aluminum hydroxide gel (AH) plus tSip were also evaluated.

Results: It revealed that tSip mixed with FIA was an effective vaccine against GBS in tilapia, while AH is toxic to tilapia.

Keywords: Adjuvant; Group B streptococcus; Tilapia; Truncated Sip; Vaccine.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adjuvants, Immunologic / administration & dosage*
Aluminum Hydroxide / administration & dosage
Animals
Antigens, Bacterial / genetics
Antigens, Bacterial / immunology*
Escherichia coli / genetics
Escherichia coli / metabolism
Fish Diseases / microbiology
Fish Diseases / prevention & control*
Freund's Adjuvant / administration & dosage*
Recombinant Proteins / genetics
Recombinant Proteins / immunology
Streptococcal Infections / prevention & control
Streptococcal Infections / veterinary*
Streptococcal Vaccines / administration & dosage*
Streptococcal Vaccines / genetics
Streptococcal Vaccines / isolation & purification
Streptococcus agalactiae / genetics
Streptococcus agalactiae / immunology*
Survival Analysis
Tilapia*
Treatment Outcome
Vaccines, Synthetic / administration & dosage
Vaccines, Synthetic / genetics
Vaccines, Synthetic / isolation & purification

Substances

Adjuvants, Immunologic
Antigens, Bacterial
Recombinant Proteins
SIP protein, Streptococcus group B
Streptococcal Vaccines
Vaccines, Synthetic
Aluminum Hydroxide
Freund's Adjuvant